P-glycoprotein, the multidrug resistance protein that actively transports a wide variety of lipophilic substrates out of cancer cells, has recently been described in some normal tissues, including the endothelium of the brain and testes. Here we show that P-glycoprotein is also expressed in oyaLian endothelium. In ovarian capilIaries, the immunolabeled protein was detected with two monodonal antibodies to P-glycoprotein. It was shown to be membrane-bound and to transport a known P-glycoprotein substrate. Expression of P-glycoprotein in endothelial cells suggests that this transport protein pIays a role in enhancing or restticting vascular permeability to lipophilic molecules. If it does, then its role may be predicted from its site of expression on the luminal or abluminal face of the capillary wall. In the region of the Supported by the Medical Research Council of Canada through Correspondence to: P.A. Stewart, Dept. Anatomy and Cell Biology, grants-in-aid (PAS,KAR).
Introduction
P-glycoprotein (P-gp) was first described in cancer cells, where it was shown to actively transport a wide variety of apparently unrelated lipophilic substances, including several antineoplastic drugs, out of the cell Gros et al., 1986; Kartner et al., 198s; Riordan et al., 1985) . Two genes in the human, MDRl and MDR2 (also called MDR3). and three in the mouse, mdrl (mdrlb), mdr2, and mdr3 (mdrla) code for the P-glycoproteins. The MRD1, mdrl, and mdr3 forms transport lipophilic drugs out of the cell, conferring multidrug resistance (ling-Wai et al., 1995; Devault and Gros, 1990) . whereas the MDR2 (MDR3) and mdr2 forms do not (Buschman et al., 1992; Schinkel et al., 1991) .
More recently, P-gp has been found in a variety of non-neoplastic cells (Bello-Reuss and Ernest, 1994; Buschman et al., 1992; Schinkel et al., 1991; Croop et al., 1989; Sugawara et al., 198% Fojo et al., 1987; Thiebaut et al., 1987) in addition to brain (Beaulieu et al., 1995; Jettt et al., 1995; Cordon-Cardo et al., 1989; Thiebaut et ai., 1989) and testicular Cordon-Cardo et al., 1989; Thiebaut et al., 1989 ) endothelium in vivo. Early hypotheses suggested that Fgp forms a protective mechanism to exclude ingested toxins from normal cells and excrete them from the body. An additional biological role for P-gp has been suggested in the normal secretion of metabolites into bile (Smit et al., 1993; Buschman et al., 1992) , urine, and directly into the lumen of the gastrointestinal tract (Thiebaut et al., 1987) . Its presence in brain capillaries suggests that it also plays a role in cerebrovascular permeability by limiting the access of some lipophilic molecules to the neuropil (Schinkel et al., 1994; Shirai et al., 1994) .
Work in this and other (Cordon-Cardo et al., 1989; Thiebaut et al., 1989) laboratories has shown that P-gp is expressed in testicular capillaries. The study reported here shows that it is also expressed in ovarian capillaries. The role of P-gp in gonadal endothelium is not known. Unlike brain capillaries, which form the blood-brain barrier, gonadal capillaries do not form a diffusion barrier (Gerdes et al., 1992; Everett and Simmons, 1958) , and blood-borne solutes cross their walls more freely than they do in brain. However, in the testis, at least, blood flow is particularly sluggish despite the high metabolic rate of testicular tissue (Setchell 1978; Setchell and Waites, 1964) . Therefore, mechanisms that affect vascular permeability may have an adaptive advantage in this vascular bed. 
I
Because future treatment modalities for cancer are being developed that include inhibitors of P-gp, an understanding of the biological role of P-gp in normal tissues and of the effects of P-gp inhibition is becoming increasingly important. Depending on its cellular location, we can suggest four hypotheses for the role of P-gp in endothelium, as illustrated in Figure 1 . The first ( Figure 1A) is that its acts to increase the extraction of lipophilic substances from blood into the tissue stroma. If this were the case, then P-gp would be localized on the abluminal membrane. Alternatively ( Figure 1B ), P-gp may act to exclude some lipophilic molecules from the stroma, as it seems to do in brain, in which case it would be localized on the luminal membrane. A third possibility ( Figure IC) is that P-gp may be involved in actively transporting lipophilic substances out of the tissue into the blood. In this case, it would also be localized on the luminal membrane. The fourth possibility ( Figure ID) is that P-gp acts to exclude lipophilic substances from the endothelial cells themselves, as it does in cancer cells. In this case, it would be localized to both luminal and abluminal membranes.
In this study we have confirmed the expression of P-gp in endothelium of brain and testis, and have further shown that it is expressed in ovarian endothelium, using the C219 and the Ab-1 monoclonal antibodies (MAbs). Western blot analysis confirmed that the protein detected in the ovary was of the same molecular weight as P-gp, is membrane-bound, and that it transports a known P-gp substrate. In addition, using confocal microscopy, we determined that P-gp is localized only to the luminal membrane in brain endothelium but is found on both luminal and abluminal membranes in gonadal capillaries. 
Materials and Methods
Immunolabeling in Tissue Sections. To localize the immunolabeled protein in endothelial cells, we took advantage of the fact that although luminal and abluminal membranes are separated by only 0.1-0.2 pm, and therefore cannot be distinguished at the light microscopic level, they diverge to surround the endothelial nucleus. At this point, they are separated by approximately 2-3 pm, a distance that is easily resolved in the light microscope.
Adult Wistar rats weighing 250-300 g were deeply anesthetized with IM injections of ketamine hydrochloride 10.0 mg/lOO g (Vetrepharm Canada; London, Ontario, Canada) and acepromazine maleate 0.5 mg/100 g (Ayerst Laboratories; MonuEal, Quebec, Canada) and decapitated. Samples of brain, testis, and ovary were removed, cryoprotected with sequential 5%. lo%, and 20% sucrose solutions (1 hr each), and frozen in isopentane cooled to -50°C with dry ice. Dissection of the ovaries was done with a dissecting microscope to ensure that the closely adherent oviduct was not included in the sample. Twenty-pm-thick sections were cut with a cryostat. P-glycoprotein was labeled with MAb C219 (ID Labs; London, Ontario, Canada) (1:loOO) and a fluoresceine isothiocyanate (FIE)-conjugated goat or rabbit and-mouse yglobulin (1:250) (Jackson Labs; Long Beach, CA). Nuclei were labeled using propidium iodide (1:10.000) (Molecular Probes; Eugene, OR). Basement membrane was labeled using a polyclonal antibody to laminin. a major basement membrane component (a gift from V. Kalnins, Department of Anatomy and Cell Biology, University of Toronto) labeled with Cy->-conjugated goat anti-rabbit y-globulin (1:50-1:lOO) (Jackson Labs). The primary antibodies were omitted in control sections of each tissue.
Fluorescently labeled specimens were examined with a Zciss LSM 410 confocal microscope equipped with a krypton/argon laser and excitationlemission filter combinations capable of detecting F I E , rhodamine, and Cy>. For each tissue sample examined, a series of xy sections were taken ENDOTHELIAL P-GLYCOPROTEIN LOCALIZATION 68 1 through the entire thickness of the tissue section (in 0.5-pm steps), and a z-axis projection of these sections was computed to determine the distribution of fluorochromes throughout the tissue. In addition, selected x-z views were computed from the xy series of images. In each instance, FIK or CY5 was pseudo-colored green, and red was used exclusively for propidium iodide-stained nuclei.
Immunodetection of P-gp. P-gp was detected by Western blot analysis using MAb C219 or Ab-1 (Oncogene Science; Uniondale, NY) as detailed in Beaulieu et al. (1995) . SDS-polyacrylamide gel electrophoresis (SDS-PAGE) was performed with a Miniprotean I1 apparatus (BioRad; Mississauga, Ontario, Canada) according to the method of Laemmli (1970) . Whole tissue homogenates or membrane preparations were resuspended in sample buffer composed of 62.5 mM Tris-HCI, pH 6.8, 10% glycerol, 2 % SDS, 5% b-mercaptoethanol, and 0.00625% bromphenol blue to a final protein concentration of 0.5 mglml. The samples were loaded on 6.25% acrylamidelbzsacrylamide (29.10.9) gels. Elecuophoresis was carried out at a constant voltage of 120 V. Proteins were transferred electrophoretically to a 0.45-pM pore size polyvinylidene difluoride (PVDF) membrane using a MilliBlot Graphite Electroblotter 1 apparatus (Millipore; Bedford, MA). The transfer buffer contained 96 mM glycine, 10 mM Tris, and 10% methanol. The transfer was carried out for 1 hr at a constant amperage of 1 mA/cm2. Hydrophobic or nonspecific sites were blocked overnight at 4'C with 5% powdered skimmed milk in Tris-buffered saline (50 mM Tris and 150 mM NaCI) containing 0.3% Tween 20 (TBST). Membranes were washed three times for 15 min in TBS. The PVDF membranes were incubated with MAb C219 (200 nglml) in TBS-T, 1% bovine serum albumin (BSA), and 0.05% NaN3 for 2 hr at 37'C. Membranes were washed three times for 15 min and incubated for 1 hr at room temperature with horseradish peroxidase-conjugated rabbit anti-mouse immunoglobulin (IgG) (1:2000) in TBS-T containing 2 % milk powder. PVDF membranes were washed four times for 10 min in TBST. P-gp was detected using chemiluminescence reagents (ECL). Molecular weights were determined with a calibration curve made with Bio-Rad standards: myosin (200 KD Photoafliity Labeling. Protein samples (50 pg) from fresh frozen ovary were incubated with '*'I-labeled iodoarylazidoprasosin (IAAP) (20 nM) in reaction buffer containing 10 mM HepeslTris, pH 7.4, and protease inhibitor cocktail. The incubation was carried out for 1 hr at 25°C in the dark and was followed by crosslinking under a w light for 5 min at 254 nm and at 4'C. Samples were then solubilized with SDS (0.5%) for 15 min at 25°C. Samples were diluted (1:5) in TBS containing 1.25% Triton X-100, 0.625% deoxycholate, and were centrifuged at 14,000 x g for 10 min. MAb C219 (1.5 pglml) was added to the supernatants and the samples were incubated overnight at 4%. Protein A-Sepharose equilibrated in TBS containing 1% Triton X-100, 0.5% deoxycholate, and 0.1% SDS (RIPA) was added (120 pllml). The suspensions were incubated for 1 hr at 25'C and centrifuged at 8000 x g for 4 min. Pellets were washed once with RIPA buffer, once with RIPA diluted 1:lO in TBS, and twice with TBS. Sample buffer was added to the pellet for SDS-PAGE and Western blot analysis as described above.
Chemic&. Dextran T-70 and protein A sepharose 4 fast flow were purchased from Pharmacia LKB Biotechnology (MontrEal, Quebec, Canada). Electrophoresis reagents were from Bio-Rad. Horseradish peroxidaseconjugated rabbit anti-mouse IgG and enhanced chemiluminescence reagents were obtained from Amersham (Oakville, Ontario, Canada). Hepes was from Boehringer-Mannheim (Lad, Quebec. Canada). Triton X-100 and X-114 and Tween 20 were from Bio-Rad and SDS was from Pierce (Rockford, IL). All other reagents were purchased from Sigma (St Louis, MO).
The studies reported here were carried out in accordance with the guidelines detailed by the Canadian Council on Animal Care and were approved by the University of Toronto Animal Care Committee.
Results

Tissue Distribution of Pgp
P-glycoprotein is expressed in microvessels in brain, testis, and ovary ( Figure 2 ). Examination of arterioles and venules in all three tissues showed that P-gp expression is confined to the endothelium; no detectable P-gp was evident in smooth muscle cells or pericytes (not shown). Control sections in which the primary antibodies were omitted show that the vascular staining is specific.
IdentifiGtion of the Immunoreactive Species in Ovary and Testis
A single band of 140 KD was identified in ovary with both C219 and Ab-1 antibodies, and it was enriched threefold in the membrane fraction ( Figure 3A) . In the testis, P-gp migrated as a 145-~D band and was enriched 20-fold in the membrane fraction ( Figure  3B ). In terms of total protein, the relative amount of P-gp found in the testis membrane was lower than that found in the ovary membrane. In ovarian tissue, binding of '*'I-labeled IAAP, a photoactivatable marker of P-gp, followed by immunoprecipitation with (2219 anibody, showed one band on the autoradiogram migrating as a ~~O -K D protein, identical to that immunodetected by Western blotting ( Figure 3C ). We were unable to detect '251-labeled IAAP binding in testicular tissues.
Cellular Localization of Pgp in Brain Endothelium
Even at the low magnification shown in Figures 2A, 2D , and 2F, P-gp can be seen to be distributed differently within the endothelial cells in brain compared to those in gonads.
In Figure 2A , endothelial nuclei (arrows) in brain are clearly outside the tubular structure defined by P-gp fluorescence. The arrows indicate two typical endothelial nuclei that have P-gp staining only on their luminal surfaces. In contrast, Figure 2B shows brain tissue reacted with antibodies to laminin to identify the basement membrane. Endothelial nuclei (arrows) are enclosed within the sleeve of basement membrane. Figure 2C shows a series of optical planes, each separated by 0.5 vm, through two endothelial nuclei in a capillary stained for P-gp, showing again that only the luminal membrane is P-gp-positive. The photomicrographs in this figure clearly demonstrate that the luminal and abluminal membranes of the endothelial cell can be distinguished, and that P-gp is localized only on the luminal membrane of brain capillaries.
Cellular Localization of Pgp in Gonadal Endothelium
Endothelial nuclei in both ovarian and testicular blood vessels were enclosed within a sleeve of P-gp-positive staining, demonstrating the abluminal location of the protein. Figure 2F shows this distribution in an ovarian capillary. Testicular capillaries had an identical appearance. That the protein is also localized on the luminal surface was determined using serial reconstruction of endothelial nuclei and their surrounding membranes, and orthogonal sections through the zy plane of the nuclei. Figure 2E is a cross-section of a small testicular postcapillary wnule. P-gp-positive staining can be seen on both the luminal and abluminal aspects of the endothelial nucleus, indicated by an asterisk. The same nucleus, seen in a 0.5-pm-thick orthogonal section taken through the plane indicated by the line in Figure 2D , is shown in Figure 2E . The orthogonal view confirms that the luminal membrane is, in fact, P-gp-positive. Ovarian vessels showed the same distribution of P-gp. Figure 2G shows an orthogonal section (0.5 pm thick) taken through the capillary shown in Figure 2F through the plane indicated by the yellow line. The lumen of the capillary is indicated by the asterisk. P-gp staining can be detected on both the luminal and abluminal membranes of two nuclei on opposite sides of the lumen.
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Occasional nuclei that were not enclosed within P-gp-positive membrane were seen in association with microvessel walls. On the basis of their shape and their relative frequency, these cells appeared to be pericytes. Staining of the basement membrane with antilaminin antibodies confirmed their identity as pericytes (not shown).
Discussion
It is becoming clear that P-gp forms a component of the blood-brain barrier that restricts the entry of some lipophilic molecules into the brain. It is expressed in all areas of the brain where barrier properties exist, including the choroid plexus epithelium, and is also found in the blood-ocular barriers . which are similar in structure and function to the blood-brain barrier (Stewart and Tuor, 1994) . Tissue culture studies have shown that cultured brain endothelial cells form a monolayer that is capable of transporting known substrates of P-gp, either out of the endothelial cells (Shirai et al., 1994; Hegmann et al., 1992; Tsuji et al.. 1992) or across a monolayer of brain endothelium in the basalto-apical direction (Shirai et al., 1994; Tatsuta et al., 1992) . Endothelial cells that were not of brain origin, and which therefore do not express blood-brain barrier properties, were unable to transport P-gp. In vivo studies in which P-gp was either inhibited (Sakata et al., 1994) or genetically disrupted (Schinkel et al.. 1994) showed that lipophilic drugs enter the brain in much greater amounts than when P-gp is functioning normally. In earlier work, one of us (RB) and collaborators have shown IAAP binding by P-gp in isolated capillaries from mouse Uettt et al., 1995) . bovine, and rat (Beaulieu et al., 1995) brain. These results further support the idea that P-gp in brain capillaries acts to exclude lipophilic substances from the endothelial cells.
Because P-gp actively pumps its substrates in only one direction, i.e., out of the cell, to restrict the entry of circulating lipophilic molecules into the brain it must be present only on the luminal aspect of the capillary wall ( Figure 1B) . Earlier studies using immunogold techniques at the electron microscopic level have localized P-gp in unfixed normal brain capillaries (Tsuji et al., 1992; Sugawara et al., 1990) and glioma vessels (Tanaka et al.. 1994) in vivo. However, the aldehyde sensitivity of P-gp and the poor preservation of ultrastructure in unfixed brain tissue make this approach problematic. Using a novel light microscopic approach, we also show that P-gp is confined to the luminal membrane in brain capillaries. Our results support these earlier conclusions, and show that our experimental approach is suitable for localizing P-gp subcellularly.
Although the role of P-gp in blood-brain barrier capillaries seems clear, its role in gonadal capillaries is much more difficult to explain. Unlike brain capillaries, ovarian (Gerdes et al., 1992; Everett and Simmons, 1958) and testicular capillaries are highly permeable to serum proteins (Kormano, 1968; Mancini et al., 1965; Everett and Simmons, 1958) , and they do not form a blood-tissue barrier in any sense. The blood-testis barrier is located at the walls of the seminiferous tubules, where it is formed by tight junctions between Sertoli cells (Fawcett et al., 1970) . Surprisingly, other blood-brain barrier-enriched proteins, such as the GLUT-1 glucose transporter and y-glutamyl transpeptidase, are also highly expressed in testicular capillaries , where their roles in vascular permeability are not understood. The localization of P-gp on both the luminal and abluminal membranes of testicular capillaries suggests that it functions to exclude lipophilic molecules from the endothelial cells themselves.
A new finding reported here is the expression of P-gp in ovarian capillaries. Our observations that the immunolabeled protein in ovary is membrane-bound, has a molecular weight of approximately 140 KD, and is capable of binding a known P-gp substrate lead us to conclude that it is, in fact P-gp, rather than an unrelated immunoreactive protein. Cordon-Cardo et al. (1989) did not detect P-gp in human ovary using either the C219 or the HYB-241 antibody. However, the age of their donor(s) was not reported. It is possible that P-gp expression in ovarian endothelium is related to the reproductive status of the gonad.
Like testicular capillaries, ovarian capillaries are highly permeable to serum proteins (Gerdes et al., 1992) . Therefore, they do not form a blood-tissue barrier. Ovarian capillaries have not been studied extensively. Whether they express the same barrier-enriched proteins as testicular capillaries is not known. The role that P-gp plays in the ovary is probably similar to its role in testicular capillaries, since it has the same membrane localization.
Because P-gp is localized in both the luminal and abliminal faces of gonadal capillary walls, we argue that it cannot be playing either a restrictive or a facilitative role in gonadal vascular permeability ( Figures 1A-1C ) but acts to export as yet unknown lipophilic molecules from the endothelial cells themselves ( Figure 1D ). Such molecules may be circulating andlor locally synthesized molecules that enter the gonadal endothelium by diffusion and which would be harmful to the cell if they were not removed.
In conclusion, we have confirmed that P-gp is localized to the luminal membrane in brain endothelium, supporting the idea that it plays an important role in the blood-brain barrier. In both ovarian and testicular endothelium, however, P-gp is found on both luminal and abluminal membranes, suggesting that it acts to exclude or export some as yet unknown substance(s) from the endothelial cells. The biological importance of this localization remains to be determined.
